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Repurposing potential
of posaconazole and grazoprevir
as inhibitors of SARS‑CoV‑2
helicase
Syed Hani Abidi1, Nahlah Makki Almansour2, Daulet Amerzhanov3, Khaled S. Allemailem4,
Wardah Rafaqat5, Mahmoud A. A. Ibrahim6, Philip la Fleur3, Martin Lukac7 & Syed Ali3*
As the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic engulfs millions
worldwide, the quest for vaccines or drugs against the virus continues. The helicase protein of
SARS-CoV-2 represents an attractive target for drug discovery since inhibition of helicase activity
can suppress viral replication. Using in silico approaches, we have identified drugs that interact with
SARS-CoV-2 helicase based on the presence of amino acid arrangements matching binding sites of
drugs in previously annotated protein structures. The drugs exhibiting an RMSD of ≤ 3.0 Å were further
analyzed using molecular docking, molecular dynamics (MD) simulation, and post-MD analyses.
Using these approaches, we found 12 drugs that showed strong interactions with SARS-CoV-2
helicase amino acids. The analyses were performed using the recently available SARS-CoV-2 helicase
structure (PDB ID: 5RL6). Based on the MM-GBSA approach, out of the 12 drugs, two drugs, namely
posaconazole and grazoprevir, showed the most favorable binding energy, − 54.8 and − 49.1 kcal/mol,
respectively. Furthermore, of the amino acids found conserved among all human coronaviruses, 10/11
and 10/12 were targeted by, respectively, grazoprevir and posaconazole. These residues are part of the
crucial DEAD-like helicase C and DEXXQc_Upf1-like/ DEAD-like helicase domains. Strong interactions
of posaconazole and grazoprevir with conserved amino acids indicate that the drugs can be potent
against SARS-CoV-2. Since the amino acids are conserved among the human coronaviruses, the virus
is unlikely to develop resistance mutations against these drugs. Since these drugs are already in use,
they may be immediately repurposed for SARS-CoV-2 therapy.
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), responsible for the ongoing global pandemic,
causes a respiratory infection found potentially fatal among elderly and immune-compromised p
 atients1,2. SARSCoV-2 is a double-stranded, positive-sense RNA virus that belongs to the Coronaviridae family. The Coronavirus
(CoV) genome frequently undergoes recombination and can produce novel strains with variations in virulence3.
There are seven strains of human coronaviruses (HCoV), namely, HCoV-229E, HCoV-NL63, HCoV-OC43,
HCoV-HKU1, Middle East respiratory syndrome (MERS)-CoV, severe acute respiratory syndrome (SARS-CoV),
and the 2019 novel coronavirus (nCoV) or SARS-CoV-24–6. The SARS-CoV and the MERS-CoV have been
responsible for large-scale epidemics in 2003 and 2012, respectively3. As the SARS-CoV-2 pandemic engulfs
millions around the world, there is a struggle to find an effective vaccine or drug against the virus. While several
drugs, including oseltamivir, lopinavir, ritonavir, arbidol, and chloroquine, have been tried with limited success,
the search for effective therapy is still underway7–11.
Due to the pivotal role that helicases play in the viral life cycle, they represent an attractive target for antiviral
therapy. To separate nucleic acid strands, energy derived from ATP hydrolysis is utilized by helicases, nucleic
acid unwinding motor proteins. This process is crucial for genome r eplication12, transcription of viral mRNAs,
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translation, disruption of RNA–protein complexes, and packaging of nucleic acids into v irions12. Depending on
whether they can bind single-stranded (ss) nucleic acid, unwind double-stranded (ds) RNA or dsDNA or both,
the polarity of the unwinding (5′ to 3′ or 3′ to 5′), and whether specific signature motifs are present in their primary sequence, helicases are classified into six superfamilies (SF1–SF6)13. Helicases belonging to SF1 and SF2
generally act as monomers or dimers on DNA or RNA substrates, whereas most of the SF3–SF6 helicases form
ring-shaped hexameric structures that encircle the nucleic acid and have roles mainly in DNA r eplication14,15.
SARS-CoV-2 helicase enzyme is a member of the SF1 that prefers ATP, dATP, and dCTP as substrates, while
hydrolyzing other NTPs as w
 ell12,16.
Several viral helicases have been used as targets in animal models of herpes simplex (HSV) and hepatitis C
(HCV) viruses17,18. The importance of helicase validity as antiviral drug targets was recently corroborated when
compounds that inhibit an HSV helicase were shown to block viral replication and disease progression in animal
models19. Similarly, much effort has been directed towards developing small-molecule inhibitors and chemicals
as drug candidates to inhibit the function of SARS-CoV-1 helicase nsP13 (SCV nsP13)17,20. Unlike the Spike
protein that is the key target for antibody-based therapeutics, the nsp13 helicase protein of SARS-CoV-2, perhaps
owing to its pivotal role in the virus life cycle, is quite conserved among the human coronavirus family21. The
conservation and functional importance of helicase makes it an ideal target for antiviral drugs.
Here, using in silico approaches, including homology modeling, molecular docking, and molecular dynamic
simulations, we found a panel of 12 drugs that show strong interactions/affinity with SARS-CoV-2 helicase
amino acids. The amino acids targeted by the drugs are highly conserved and appear to be crucial for helicase
function, indicating that the drugs will be potent against SARS-CoV-2 and that the virus is unlikely to develop
resistance mutations against these drugs. Since these drugs are currently used for antiviral and chemotherapeutic
purposes, they can be repurposed to treat SARS-CoV-2 without an extensive drug safety profiling process. This
will especially benefit regions without high-level biosafety facilities for testing viral drugs, will and provide a
timely solution for SARS-CoV-2 t herapy22.

Computational methodology

Sequence retrieval, analysis of domain architecture, and conservation. SARS-CoV-2 helicase
amino acid sequence was retrieved in FASTA format from the National Center for Biotechnology (NCBI) Genbank (NCBI genome ID: MN908947). Conserved domains in the retrieved structure were mapped using the
NCBI Conserved Domain Search (CDD) tool tool v3.1923. Conserved Domain Architecture Retrieval Tool
(CDART) and Subfamily Protein Architecture Labeling Engine (SPARCLE) tools were used to identify sequences
sharing of domain architecture with our query (SARS-CoV-2 helicase) sequence, and the search was refined to
identify only human virus sequences24.
Retrieval of SARS‑CoV‑2 helicase structure. For our analysis, experimental 3D structure of SARS-

CoV-2 helicase (PDB ID: 5RL6) was retrieved from PDB. The structure was visually inspected in Discovery Studio Visualizer version 4.0 (DSV4.0; Dassault Systèmes BIOVIA, Discovery Studio Visualizer). Subsequently, the
structure was verified using the Verify 3D tool, while the energy minimization and validation were performed
using the GROMACS, ERAAT, Verify3D, and Ramachandran plot analysis implemented in DSV4.025–27.

Prediction of drug that can interact with SARS‑CoV‑2 helicase protein and retrieval of drug
structures. Drug ReposER tool, a web server that uses a modified version of the SPRITE search engine to

identify similar amino acid arrangements to known drug binding interfaces for potential drug repositioning,
was used to predict/identify drugs that could interact with the SARS-CoV-2 helicase based on the presence of
amino acid arrangements matching binding sites of drugs in previously annotated protein structures28. The tool
predicts the binding of drugs with query protein based on RMSD. We used RMSD of 3.0 Å or less as the threshold, and structures of drugs exhibiting RMSD 3.0 Å and under were retrieved from PubChem Database in 3D
SDF format. The 3D geometrical structures of drugs were then minimized by the Merck Molecular Force Field
94 (MMFF94S) force field using SZYBKI s oftware29,30. Before docking analysis, SDF structures were converted
to PDBQT format using the OpenBabel tool, and polar hydrogens were added to the drug structures during
conversion31.

Drug‑protein docking. The protonation state of SARS-CoV-2 helicase was first investigated using the H
 ++
s erver32. In H
 ++ calculations, the following physical conditions were employed: pH = 6.5, internal dielectric = 10,
external dielectric = 80 and salinity = 0.15. The SARS-CoV-2 helicase was then prepared based on the AutoDock
protocol33. The preparation involved merging of nonpolar hydrogens, addition of polar hydrogens, and generation of PDBQT files using AutoDock Tools34. Subsequently, molecular docking calculations were performed to
predict and analyze the drug-helicase interactions using AutoDock Vina software35. The Vina parameters were
kept to the default, except the exhaustiveness parameter was set to 200. Blind docking was employed in which
the binding site was realized by a docking box around the whole protein. The grid spacing value was set to 1.0 Å.
Visualization of docking poses and analysis of drug-protein interactions was performed using Discovery Studio
Visualizer version 4.0 (DSV4.0; Dassault Systèmes BIOVIA, Discovery Studio Visualizer).
MD simulations and MM‑GBSA energy calculations. Molecular dynamics (MD) simulations for

the repurposed drugs complexed with SARS-CoV-2 helicase were performed using AMBER16 software36. Two
AMBER force fields were used to describe the drug and helicase —namely, general AMBER force field (GAFF)37
and AMBER force field 14SB38, respectively. The atomic partial charges of the repurposed drugs were assigned
using the restrained electrostatic potential (RESP) a pproach39 at the HF/6-31G* level with the assistance of
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Figure 1.  Protein and domain classification. Conserved domains in the SARS-CoV-2 structure were mapped
using the NCBI Conserved Domain Search (CDD) tool v3.19. The SARS-CoV-2 helicase was found to be
a DNA2 superfamily helicase with two significant domains: DEAD-like helicase C (spanning amino acids
323–592) and DEXXQc_Upf1-like (spanning amino acids 272–443), containing Walker A motif (GTGKSH) at
N-terminus that is involved in ATP binding. Two additional functional domains ZBD_cv_Nsp13-like (spanning
amino acids 1–95) and 1B_cv_Nsp13-like (spanning amino acids 150–228) were also found in the sequence.
(note: the figure is an original image generated by CDD v3.19 tool).
Gaussian09 software40. The docked drug-helicase complexes were water solvated with 15 Å distances between
the box edge and atoms of the solute. The solvated systems were minimized by 5000 steps and afterward gently
heated from 0 to 300 K over 50 ps. Using periodic boundary conditions and NPT ensemble, the systems were
equilibrated for 1 ns, and production stages of 100 ns were executed. Particle Mesh Ewald (PME) method41 with
a direct space cut-off of 12 Å was employed to treat the long-range electrostatic interactions. Langevin dynamics
with a gamma_ln parameter of 1.0 was adopted to retain the temperature constant at 298 K. Berendsen barostat
with a relaxation time of 2 ps was employed to control the pressure of the system42. All bonds involving hydrogen
atoms were constrained using the SHAKE option, and the time step was set to 2 fs. Over the production stage,
uncorrelated snapshots were collected over every 20 ps for binding energy calculations. The binding energies
were calculated using the molecular mechanical-generalized Born surface area (MM-GBSA) approach43 with a
modified GB model (igb = 2) implemented in AMBER16 software. The binding energy (ΔGbinding) was evaluated
as follows:


Gbinding = Gdrug−helicase − Gdrug + Ghelicase
where the energy term (G) is estimated as:

G = Evdw + Eele + GGB + GSA
Evdw and Eele are van der Waals and electrostatic energies, respectively. GGB is the electrostatic solvation free energy
calculated from the generalized Born equation and GSA is the nonpolar contribution to the solvation free energy
from the solvent-accessible surface area (SASA). All molecular dynamics simulations were executed with pmemd.
cuda implemented in AMBER16. All molecular docking and molecular dynamics calculations were performed
on the CompChem GPU/CPU cluster (hpc.compchem.net).

Results

Analysis of domain architecture and conservation of domains. The conserved domains in the

SARS-CoV-2 helicase sequence were mapped using the NCBI CDD tool, and the CDART and SPARCEL tool
was used to identify sequences sharing domain architecture with our query (SARS-CoV-2 helicase) sequence.
The SARS-CoV-2 helicase was found to be a DNA2 superfamily helicase with two significant domains: DEADlike helicase C (cd17934) and DEXXQc_Upf1-like (accession number COG1112), containing Walker A motif
at N-terminus that is involved in ATP binding (Fig. 1). Two additional functional domains, ZBD_cv_Nsp13like (spanning amino acids 1–95) and 1B_cv_Nsp13-like (spanning amino acids 150–228), were also found in
the query sequence (Fig. 1). Analysis of the conserved domain architecture (architecture ID: 13027813) suggested that the DEXXQc_Upf1-like and DEAD-like_helicase_C domains were conserved in helicases from
70 different organisms, including humans, fungi, bacteria, and viruses. Analysis of only viral sequences suggested that DEXXQc_Upf1-like and DEAD-like_helicase_C domains were conserved features of coronavirus
helicase, where helicase from 28 different coronaviruses, including SARS and MERS, were found to possess the
DEXXQc_Upf1-like and DEAD-like_helicase_C domain (Table 1). The sequences from human coronaviruses
were used for further analysis.

Analysis of the drug‑protein docking revealed strong binding affinities of drugs with the
SARS‑CoV‑2 helicase. Before docking, the SARS-CoV-2 structure (Fig. 2A) was validated using ERAAT,

VERIFY 3D, GROMACS, and Ramachandran plot analysis. The structure passed the 3D verification (performed
using Verify 3D software), with 92.83% of the residues averaged 3D-1D score ≥ 0.2. The ERAAT quality score for
the structure was 90.64. The structures were also found valid on the Ramachandran plot as most (99.6%) of the
amino acids were under the permissible (Fig. 2B).
Further, validation of the docking approach was confirmed by performing blind docking (assuming drug
binding site to be anywhere in the protein) on a previously reported complex of HCV NS3 helicase bound to
inhibitor ITMN-3479 (PDB ID: 3RVB)44. Our results revealed that the observed binding site/pose and drugprotein interaction were the same as reported in the crystal structure of the complex, indicating that the docking
strategy was efficient and valid (Fig. 2C).
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No

Identifier

Description

Organism

1

ACU31046

Helicase, partial

Bat SARS-CoV Rs806/2006

2

YP_008439223

nsp13

Bat coronavirus CDPHE15/USA/2006

3

YP_459942

nsp13

Human coronavirus HKU1

4

NP_742139

Coronavirus nsp10 (MB, NTPase/HEL)

Bovine coronavirus

5

ABB77060

Helicase, partial

Pipistrellus bat coronavirus HKU5

6

ABB77058

Helicase, partial

Pipistrellus bat coronavirus HKU5

7

ABB77061

Helicase, partial

Bat coronavirus HKU6

8

ABB77050

Helicase, partial

Rhinolophus bat coronavirus HKU2

9

ABB77053

Helicase, partial

Tylonycteris bat coronavirus HKU4

10

ABB77054

Helicase, partial

Tylonycteris bat coronavirus HKU4

11

ABB77057

Helicase, partial

Pipistrellus bat coronavirus HKU5

12

ABB77056

Helicase, partial

Pipistrellus bat coronavirus HKU5

13

ABB77051

Helicase, partial

Rhinolophus bat coronavirus HKU2

14

ABB77052

Helicase, partial

Tylonycteris bat coronavirus HKU4

15

ABB77055

Helicase, partial

Tylonycteris bat coronavirus HKU4

16

NP_839966

Putative coronavirus nsp10 (MB, NTPase/HEL)

Porcine epidemic diarrhea virus

17

YP_209240

nsp13; zinc-binding domain and helicase

Murine hepatitis virus strain JHM

18

ABD15361

HELICASE, partial

Miniopterus bat coronavirus HKU8

19

YP_009555254

nsp10

Human coronavirus OC43

20

ABO88148

Helicase, partial

Bat coronavirus Anhui/911/2005

21

ABG11967

Helicase, partial

Bat coronavirus (BtCoV/A434/2005)

22

ABG11968

HELICASE, partial

Bat coronavirus A515/2005

23

YP_009047224

nsp13 protein

Middle East respiratory syndrome-related coronavirus

24

NP_828870

nsp13-pp1ab (ZD, NTPase/HEL)

Severe acute respiratory syndrome-related coronavirus

25

ABG11969

Helicase, partial

Bat coronavirus A527/2005

26

ABG11966

Helicase, partial

Bat coronavirus (BtCoV/355A/2005)

27

5WWPA

Chain A, Crystal Structure Of Middle East Respiratory Syndrome Coronavirus Helicase (MERSCoV Nsp13)

Human betacoronavirus 2c EMC/2012

28

5WWPB

Chain B, Crystal Structure Of Middle East Respiratory Syndrome Coronavirus Helicase (MERSCoV Nsp13)

Human betacoronavirus 2c EMC/2012

Table 1.  Domain architecture conservation in viruses. CDART and SPARCLE tools were used to identify
sequences sharing of domain architecture with our query (SARS-CoV-2 helicase) sequence. The search was
refined to identify only human virus sequences, identified by NCBI identifier in column 2, which are shown
in the Table. The Table also describes the nature of protein in all the shortlisted sequences and the organism to
which they belong.

Figure 2.  Validation of structure and docking strategy: (A) Structure of SARS-CoV-2 helicase used in the study,
(B) Ramachandran plots for SARS-CoV-2 helicase structure (PDB ID: 5RL6) used in the study, and (C) Docking
strategy was validated by re-docking a previously published inhibitor ITMN-3479 on its receptor. Poses of ligand
bound to the receptor generated after docking in our study (left, ligand, and protein are shown in red and dark
grey, respectively) and retrieved from PDB (right; ligand and protein are shown in pink and green, respectively)
are shown, while the bottom panel shows amino acid interactions reported for each ligand and observed in our
study.
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Drug ReposER tool was used to predict/identify drugs that could interact with the SARS-CoV-2 helicase
based on the presence of amino acid arrangements matching binding sites of drugs in for previously annotated
protein structures. In the first step, the SARS-CoV-2 structure was loaded to the server that used PDB coordinate
files to search and compare amino acid side chain arrangements that match those found in drug binding sites
in previously annotated protein structures. The tool predicts the binding of drugs with query protein based on
RMSD. In the next step, we set a threshold of RMSD ≤ 3.0 Å and found sites for 12 previously annotated drugs
having RMSD ≤ 3.0 Å. These drugs were individually docked to the SARS-CoV-2 helicase protein analysis of the
drug-protein interactions revealed that the drugs exhibited strong binding affinity with SARS-CoV-2 helicase,
ranging from − 10.3 to − 7.5 kcal/mol, where teniposide, grazoprevir and posaconazole showed the lowest binding energies with a docking score of − 10.3, − 10.1 and − 9.5 kcal/mol, respectively (Fig. 3).

MD simulations and MM‑GBSA analysis. For accurate estimation of the binding affinities of the proposed drugs as SARS-CoV-2 helicase inhibitors, all docked drug-helicase complexes were solvated and subjected
to molecular dynamics (MD) simulation of 100 ns. Based on the collected snapshots, binding energies were
estimated using the molecular mechanics-generalized Born surface area (MM-GBSA) approach over the first 25,
50, and 100 ns MD simulations (Fig. 4). As shown in Fig. 4, among the examined drugs as potential SARS-CoV-2
helicase inhibitors, posaconazole and grazoprevir exhibited the most promising binding affinities towards SARSCoV-2 helicase. The estimated MM-GBSA binding energies of posaconazole and grazoprevir were nearly constant over the MD course, with values of − 49.4 and − 48.1, − 51.3 and − 52.7, and − 54.8 and − 49.1 kcal/mol
over 25, 50, and 100 ns MD, respectively. The surpass potentiality of grazoprevir as a SARS-CoV-2 helicase
inhibitor is returned to its capability to exhibit multiple hydrogen bonds, van der Waals interactions in addition
to hydrophobic and pi-based interactions with the key amino acids within the active site (Fig. 3). More precisely,
grazoprevir forms three hydrogen bonds with ASN177, THR413, and ARG560 amino acid with bond lengths of
2.65, 1.91, and 2.88 Å, respectively.
To analyze the principle interactions in posaconazole- and grazoprevir-SARS-CoV-2 helicase complexes,
MM-GBSA binding energy decomposition was executed over the MD course of 100 ns (Table 2). Interestingly,
Vander Waals energy (Evdw) was found to be the predominant component in the interactions of posaconazoleand grazoprevir with SARS-CoV-2 helicase complexes, with binding energies of − 77.9 and − 68.7 kcal/mol,
respectively (Table 2). Additionally, for the two drug-protein complexes, the electrostatic energies (Eele) of− 24.6
and − 28.4 kcal/mol, respectively, were also favorable (Table 2).
Post‑dynamics analyses. To evaluate the stability of the interaction of the posaconazole and grazoprevir

inside the active site of SARS-CoV-2 helicase, structural and energetic analyses were carried out over the 100 ns
MD simulations. Analyses involve binding energy per frame, hydrogen bond lengths, and root-mean-square
deviation (RMSD).

Binding energy per frame. The stability of posaconazole and grazoprevir inside the SARS-CoV-2 helicase active
site was scrutinized via inspecting the correlation between the binding energy per frame and time (Fig. 5). The
most exciting aspect of the data illustrated in Fig. 5 was the overall stability of posaconazole and grazoprevir
towards SARS-CoV-2 helicase through the MD course of 100 ns with average values − 54.8, − 49.1 kcal/mol,
respectively.
Hydrogen bond length. Hydrogen bond analysis was executed on the production MD trajectory, and the results
are presented in Table 3. What stands out in Table 3 is the high stability of two identified drugs towards SARSCoV-2 helicase. Posaconazole and grazoprevir form an essential hydrogen bond with ASP315 and LEU141 with
an average bond length of 2.7 and 2.8 Å, respectively (Table 3). The posaconazole and grazoprevir showed a
persistent 95.6 and 93.9% of the production MD trajectory snapshots, respectively (Table 3). Overall, these postdynamics outcomes illustrated proof for the stability of posaconazole and grazoprevir in complex with SARSCoV-2 helicase.
Root‑mean‑square deviation. The structural changes of posaconazole and grazoprevir in complex with SARSCoV-2 helicase were estimated using root-mean-square deviation (RMSD). The conformational change of backbone atoms was evaluated throughout the 100 ns MD simulations and compared to the initial conformation
(Fig. 6). As shown in Fig. 6, the overall stability of posaconazole and grazoprevir was observed with an average
RMSD value of 0.20 and 0.26 nm, respectively. Eventually, the presented results proved that the two drugs are
tightly bonded with, and do not influence the overall topology of, SARS-CoV-2 helicase.

Drug‑protein docking revealed that Posaconazole and Grazoprevir target conserved residues
in functional domains of the SARS‑CoV‑2 helicase. Interestingly, most of the amino acids that formed

interactions with posaconazole and grazoprevir are crucial for helicase activity (Fig. 1) and were found to be
conserved in two or more known human coronavirus helicases (Fig. 7). Among these, 10 out of 11 residues targeted by grazoprevir were conserved among all human coronaviruses, while the remaining 1 residue (THR413)
was only conserved in SARS-CoV-2, SARS-CoV-1, and MERS (Fig. 7). Similarly, 10 out 12 residues targeted by
posaconazole were conserved among all human coronaviruses, while the remaining two residues (THR416 and
ARG178) were only conserved in SARS-CoV-2, SARS-CoV-1, and MERS (Fig. 7). These residues targeted by
both the drugs are part of DEAD-like helicase C and DEXXQc_Upf1-like/DEAD-like helicase domains (Fig. 1).
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Figure 3.  2D representations of the predicted binding modes and scores of the investigated twelve drugs inside
the active site of the SARS-CoV-2 helicase.
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Figure 4.  Calculated MM-GBSA binding energies for the investigated drugs as SARS-CoV-2 helicase
inhibitors.

Estimated MM-GBSA binding energy (kcal/mol)
Drug

∆EVDW

∆Eele

∆EGB

∆ESUR

∆Ggas

∆Gsolv

∆Gbinding

Posaconazole

− 77.9

− 24.6

56.8

− 9.1

− 99.8

47.7

− 54.8

Grazoprevir

− 68.7

− 28.4

56.7

− 8.7

− 96.9

48.0

− 49.1

Table 2.  MM-GBSA binding energies decomposition for the top two investigated drugs in complex with
SARS-CoV-2 helicase through the MD course of 100 ns.

Figure 5.  Evaluated MM-GBSA binding energy per frame for posaconazole (in black) and grazoprevir (in red)
towards SARS-CoV-2 helicase throughout 100 ns MD simulation.

Discussion

Here, using in silico analyses, we identify drugs that may interact and inhibit the SARS-CoV-2 helicase, nsp13.
The SARS-CoV-2 structure was loaded to the server that used PDB coordinate files to search and compare amino
acid side chain arrangements that match those found in the drug binding sites in previously annotated protein
structures. Drugs thus identified were then shortlisted for docking studies using a threshold of RMSD ≤ 3.0 Å46.
This approach gave us 12 drugs, namely posaconazole, grazoprevir, tipranavir, paclitaxel, saquinavir, teniposide,
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Drug

Acceptor

Donor

Distance (Å)a

Angle (°)a

Occupied (%)b

Posaconazole

ASP315@OD1

Posaconazole597@O2-H41

2.7

164

95.6

Grazoprevir

LEU412@O

Grazoprevir597@N4-H48

2.8

161

93.9

Table 3.  Hydrogen bonds exhibited between the key residues and the most promising drugs against SARSCoV-2 helicase. a The hydrogen bonds are inspected by the acceptor–donor atom distance of < 3.5 Å and
acceptor-H-donor angle of > 120°. b Occupancy is employed to estimate the stability and strength of the
hydrogen bond.

Figure 6.  Root mean square deviation (RMSD) of the backbone atoms from the initial structure for
posaconazole (in black) and grazoprevir (in red) with the SARS-CoV-2 helicase over 100 ns MD simulations.

indinavir, atazanavir, nevirapine, minocycline, cyclothiazide, and darunavir, exhibiting strong binding with
SARS-CoV-2 helicase protein. Out of these 12, posaconazole, and grazoprevir were found to be the most potent
(Figs. 3 and 4).
Most of the amino acids targeted by grazoprevir and Posaconazole ((10/11 and 10/12, respectively) were
conserved among all human coronaviruses. Additionally, these residues are part of the crucial DEAD-like helicase C and DEXXQc_Upf1-like/ DEAD-like domains of helicase (Table 1), indicating their key roles in the
helicase activity. Upf1 domain of the helicase is crucial for nonsense-mediated mRNA decay. It retains a tight
grip on nucleic acids during helicase action47. On the N-terminus, Upf1 has Walker A motif, which functions as
a phosphate-binding P-loop used by the helicase to bind NTP using another motif, i.e. Walker B, which acts as
an Mg2+ co-factor-binding loop48. The A and B motifs of Walker-type NTP-binding pattern are perhaps the only
sequence elements shared by all known groups of h
 elicases49. The DEAD helicases have a diverse role in all phases
of RNA transcription, including mRNA splicing, export, translation, stability, etc.50. Although RNA helicases are
large in number, yet each RNA helicase seems to have its significance in RNA processing. For example, a study
performed in yeast showed that functional loss of one DEAD-box helicase could not be supplemented by another
related helicase51. In addition to RNA transcription, DEAD-box helicases also aid in ribosome biosynthesis by
mediating interactions between small nucleolar and ribosomal R
 NA52. In the SARS virus, 1B regulatory domain
of Nsp13 helicase is involved in nucleic acid substrate binding.
Both grazoprevir and Posaconazole exhibited strong binding energies with the helicase protein, i.e. − 54.8
and − 49.1 kcal/mol, respectively, based on the MM-GBSA approach over the first 100 ns MD simulations. In
the MM-GBSA analysis, Vander Waals forces were found to be the principal force of interaction between the
drugs and protein, and the interactions were electrostatically favorable. Considering the essential nature of
motifs DEXXQc_Upf1-like and DEAD-like helicase C in helicase function, it may be speculated that the drugs
strongly interacting with these motifs will potently inhibit the helicase activity and will, therefore, be highly
effective as antivirals.
Both the shortlisted drugs have well-established safety profiles. Posaconazole is a potent triazole antifungal
drug used to treat invasive fungal infections in severely immunocompromised patients. In the clinical trial, higher
doses (up to 1600 mg/day) had no adverse effects as compared to lower doses53. Similarly, grazoprevir is a potent
antiviral drug used against HCV and inhibits HCV NS3/4A, a serine protease e nzyme53. The adverse effects of
this drug, at all intensities, are limited to fatigue, headache, and nausea53. Based on the well-characterized safety
profiles53, the two drugs can be evaluated for immediate clinical use.
In conclusion, grazoprevir and posaconazole drugs show considerable potential for repurposing as antivirals
against SARS-CoV-2. In the motifs, DEXXQc_Upf1-like and DEAD-like helicase C, conservation of the interacting amino acid residues throughout human coronaviruses indicates that the drugs will effectively inhibit
SARS-CoV-2 helicase and that the virus is unlikely to develop resistance to these antivirals. Given the emergent
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Figure 7.  Sequence alignment of known human coronaviruses sharing helicase domain architecture: Multiple
sequence alignment (ranging from amino acid 3–596, numbered according to their position in the helicase
protein) was performed employing ‘Clustal W’. Conserved residues/sites are highlighted in black color,
residues conserved in two or more sequences are shown in black font, while differences are shown in grey font.
Publication quality alignment was prepared using the ENDscript s erver45.
need for treatment against SARS-CoV-2, we propose immediate trials to evaluate the repurposing of these two
drugs as antivirals.
Received: 11 November 2020; Accepted: 13 April 2021
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